Persistent tachycardia in clozapine treated patients: A 24-hour ambulatory electrocardiogram study

[1]  K. Ronaldson.  Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management , 2017, CNS Drugs.

[2]  L. Lindström,et al.  Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections , 2017, International clinical psychopharmacology.

[3]  D. Conen,et al.  Heart Rate Variability and Sleep-Related Breathing Disorders in the General Population. , 2016, The American journal of cardiology.

[4]  M. Owen,et al.  Reasons for discontinuing clozapine: A cohort study of patients commencing treatment , 2016, Schizophrenia Research.

[5]  J. MacCabe,et al.  Pharmacological interventions for clozapine-induced sinus tachycardia. , 2016, The Cochrane database of systematic reviews.

[6]  L. Thomas,et al.  Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study , 2014, Open Heart.

[7]  T. Pollmächer,et al.  Olanzapine and clozapine differently affect sleep in patients with schizophrenia: Results from a double-blind, polysomnographic study and review of the literature , 2014, Schizophrenia Research.

[8]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[9]  C. Correll,et al.  Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? , 2013, The Journal of clinical psychiatry.

[10]  L. Køber,et al.  Resting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. , 2013, European heart journal.

[11]  Finn Gyntelberg,et al.  Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study , 2013, Heart.

[12]  D. Vancampfort,et al.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. , 2013, Schizophrenia bulletin.

[13]  Abraham Weizman,et al.  &bgr;-Adrenergic Antagonists for the Treatment of Clozapine-Induced Sinus Tachycardia: A Retrospective Study , 2009, Clinical neuropharmacology.

[14]  E. O’Brien,et al.  Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations , 2008, Hypertension.

[15]  Michael Bursztyn,et al.  Blunted heart rate dip during sleep and all-cause mortality. , 2007, Archives of internal medicine.

[16]  J. Lieberman,et al.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.

[17]  Giuseppe Mancia,et al.  Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. , 2006, Journal of hypertension.

[18]  N. Zakopoulos,et al.  Impact of Obesity on 24-Hour Ambulatory Blood Pressure and Hypertension , 2005, Hypertension.

[19]  D. Goff,et al.  Adverse Cardiac Effects Associated With Clozapine , 2005, Journal of clinical psychopharmacology.

[20]  M. Kotler,et al.  Association of autonomic dysfunction and clozapine , 2001, British Journal of Psychiatry.

[21]  A. Dyer,et al.  Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. , 1999, American journal of epidemiology.

[22]  H. Lithell,et al.  Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. , 1987, European heart journal.